Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.48 USD | +4.53% | -0.40% | -50.89% |
May. 02 | North American Morning Briefing : Stock Futures -2- | DJ |
May. 01 | UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating | MT |
Financials (USD)
Sales 2024 * | 670M | Sales 2025 * | 769M | Capitalization | 3.29B |
---|---|---|---|---|---|
Net income 2024 * | -190M | Net income 2025 * | -119M | EV / Sales 2024 * | 4.31 x |
Net cash position 2024 * | 401M | Net cash position 2025 * | 493M | EV / Sales 2025 * | 3.64 x |
P/E ratio 2024 * |
-17.1
x | P/E ratio 2025 * |
-27.8
x | Employees | 1,259 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.58% |
Latest transcript on 10x Genomics, Inc.
1 day | +4.53% | ||
1 week | -0.40% | ||
Current month | -6.15% | ||
1 month | -23.11% | ||
3 months | -36.97% | ||
6 months | -30.82% | ||
Current year | -50.89% |
Managers | Title | Age | Since |
---|---|---|---|
Serge Saxonov
FOU | Founder | 47 | 12-07-01 |
Ben Hindson
FOU | Founder | 49 | 12-07-01 |
Justin McAnear
DFI | Director of Finance/CFO | 49 | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Stuelpnagel
CHM | Chairman | 66 | 13-07-31 |
Kim Popovits
BRD | Director/Board Member | 65 | 20-03-25 |
Mathai Mammen
BRD | Director/Board Member | 57 | 17-08-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 27.48 | +4.53% | 2,385,262 |
24-05-02 | 26.29 | -2.34% | 2,019,269 |
24-05-01 | 26.92 | -8.06% | 6,513,049 |
24-04-30 | 29.28 | +3.10% | 2,596,760 |
24-04-29 | 28.4 | +2.94% | 1,459,048 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.89% | 3.29B | |
-1.89% | 12.56B | |
-9.59% | 7.68B | |
-1.31% | 5.29B | |
+21.82% | 5.24B | |
+0.02% | 4.57B | |
+6.42% | 2.6B | |
-10.02% | 2.2B | |
-8.29% | 1.79B | |
+1.72% | 1.76B |
- Stock Market
- Equities
- TXG Stock